18例炎性乳腺癌的临床分析

目的探讨综合治疗对炎性乳腺癌生存率的影响.方法共收治18例炎性乳腺癌患者,11例接受化疗、放疗及手术治疗,4例接受化疗、放疗、手术及内分泌治疗,3例作放疗与化疗.随访时间为6个月～3年.结果结果显示,6个月、1年、2年及3年总生存率分别为88.9%(16/18)、73.3%(11/15)、50%(6/12)、27.3%(3/11).接受综合治疗的患者总生存率为93.9%(14/15)、84.6%(11/13)、54.5%(6/11)、30%(3/10).结论炎性乳腺癌是最具侵袭性的乳腺肿瘤,也是预后极差的实体肿瘤之一.综合治疗可以改善其总生存率.

Analysis of 18 Cases of Patients with Inflammatory Breast Carcinoma

Objective: To assess whether combined multimodality therapy (CMT) provides better survival rates of patients with inflammatory breast carcinoma (IBC). Methods: 18 patients with IBC were treated according to our program. 11 patients received chemotherapy, radiotherapy and surgery (CT RT S). 4 patients received chemotherapy, radiotherapy, surgery and endocrinotherapy (CT RT S H). 3 patients received chemotherapy and radiotherapy without surgery (CT RT). Follow - up times from diagnosis were 6 months to 3 years. Results: The 6 - month, 1 -, 2 - and 3 - year survival rates of these patients were 88. 9 % (16/18), 73. 3 % (11/15), 50 % (6/12), 27. 3 % (3/11 ) respectively. For patients treated with CMT ("CT RT S"and"CT RT S H")were,93. 9 % (14/15), 84. 6 % (11/13), 54. 5 % (6/11), 30 % (3/10) respectively. Conclusion: Inflammatory breast carcinoma is the most aggressive breast neoplasm and one of the most ominous solid tumor with poor prognosis. Accordingly, aggressive CMT may prolong survival rates.